Chris Ryan

Durvalumab plus chemotherapy, followed by durvalumab maintenance with or without olaparib, improved responses in advanced endometrial cancer.

Vibostolimab plus pembrolizumab was not superior to pembrolizumab monotherapy in pretreated PD-L1–positive advanced cervical cancer.

XB2001 plus chemotherapy improved safety and was tied to a trend toward improved overall survival in pretreated advanced pancreatic cancer.

Tafasitamab plus lenalidomide has been granted priority review in China for transplant-ineligible, relapsed/refractory diffuse large B-cell lymphoma.

The FDA placed partial clinical holds on trials evaluating azenosertib in advanced solid tumors, including ovarian cancer and uterine serous carcinoma.

The FDA placed a partial clinical hold on a phase 1 trial evaluating YL202 in select patients with advanced non–small cell lung cancer or breast cancer.

The FDA has approved pembrolizumab plus carboplatin and paclitaxel, followed by pembrolizumab alone, for primary advanced or recurrent endometrial carcinoma.

A BLA is seeking the approval of subcutaneous amivantamab for all currently approved indications of the IV formulation in EGFR+ NSCLC.

Zanubrutinib was associated with improved cost savings and quality-adjusted life year benefits vs acalabrutinib in B-cell malignancies.

The FDA had approved durvalumab plus, followed by single-agent durvalumab, for dMMR primary advanced or recurrent endometrial cancer.

Zanubrutinib/venetoclax elicited a 100% overall response rate in untreated chronic lymphocytic leukemia harboring 17p deletions or TP53 mutations.

The FDA granted full approval to selpercatinib for select patients with advanced or metastatic RET fusion–positive thyroid cancer.

Decreases in variant allele frequency in ctDNA were linked to improved CBR with imlunestrant in estrogen receptor–positive, HER2-negative breast cancer

The FDA has granted priority review to the supplemental NDA seeking the approval of osimertinib in EGFR-mutated stage III non–small cell lung cancer.

The European Commission granted orphan drug designation to UCART22 for acute lymphoblastic leukemia.

Lunresertib plus camonsertib received FDA fast track designation for select patients with platinum-resistant ovarian cancer.

A clinically meaningful but not statistically significant improvement in OS was observed with uproleselan plus chemotherapy vs chemotherapy alone in primary refractory AML.

Daratumumab plus VRd increased rates of MRD negativity in newly diagnosed, transplant-eligible multiple myeloma.

The xM and xM NeXT Personal® Dx MRD assays are now available for detecting residual disease and early cancer recurrence in patients with cancer.

Trastuzumab deruxtecan improved PFS vs chemotherapy in pretreated, HR-positive, HER2-low or -ultralow metastatic breast cancer.

Osimertinib after definitive chemoradiotherapy improved PFS vs placebo in locally advanced, EGFR-mutated non–small cell lung cancer.

Induction encorafenib/binimetinib before nivolumab/ipilimumab did not improve PFS in unresectable or metastatic BRAF V600E/K–positive melanoma.

Ivonescimab monotherapy improved PFS vs pembrolizumab in the first-line treatment of PD-L1–positive NSCLC in China.

The FDA accepted the resubmission of the BLA for first-line zolbetuximab in CLDN18.2-positive, HER2-negative, advanced gastric or GEJ adenocarcinoma.

The FDA approved liso-cel for the treatment of adult patients with relapsed/refractory mantle cell lymphoma after at least 2 prior lines of therapy, including a BTK inhibitor.

PSMA response was associated with improved metastasis-free survival in oligometastatic castration-sensitive prostate cancer.

The FDA granted fast track designation AFM24 plus atezolizumab for advanced EGFR wild-type non–small cell lung cancer.

The FDA granted priority review to inavolisib plus palbociclib/fulvestrant for HR-positive, HER2-negative, advanced breast cancer with PIK3CA mutations.

The FDA has received a new drug application for the use of TLX007-CDx in the preparation of PSMA PET imaging of prostate cancer.

Positive PD-L1 expression was associated with worse survival in metastatic papillary renal cell carcinoma.